{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:08:53Z","timestamp":1764688133101,"version":"3.40.5"},"reference-count":16,"publisher":"Georg Thieme Verlag KG","issue":"05","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"AGO Studiengruppe"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Geburtshilfe Frauenheilkd"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Real-world data on treatment patterns and outcomes in recurrent or metastatic cervical cancer (r\/mCC) are lacking.<\/jats:p><jats:p>This first national quality assurance initiative was a retrospective analysis of patients with r\/mCC diagnosed between 2018 and 2022, who were identified from medical records of 31 gynecologic cancer centers in Germany. Patient demographic and clinical characteristics, treatment patterns, and clinical outcomes were assessed descriptively. Progression-free (PFS) and overall survival (OS) were calculated using Kaplan-Meier analysis.<\/jats:p><jats:p>A total of 503 eligible patients (median age 55 years) were analyzed for r\/mCC. 276\/503 patients (55%) received first-line (1L) chemotherapy (platinum combination: 247\/276; 79%) followed by targeted antibody therapy with bevacizumab (177\/247; 72%), immunotherapy (19\/247; 8%), or both combined (50\/247; 20%). 111\/503 (22%) received chemotherapy only (platinum combination: 64\/111; 58%, platinum mono: 35\/111; 31%, or platinum-free: 12\/111; 11%), and 110\/503 (22%) did not receive any systemic treatment (the remaining 6\/503 patients received immunotherapy only). For these subgroups after a median follow-up of 16 months, the PFS was 12 months (95% CI 11\u201314), 8.8 months (95% CI 7.1\u201311), and 3 months (95% CI 2.3\u20134.8), and OS was 25 months (95% CI 21\u201331), 17 months (95% CI 14\u201322), and 3.6 months (95% CI 2.8\u20135.3), respectively. 176\/283 (62%) patients who developed progressive disease (PD) were treated with second-line (2L) therapy.<\/jats:p><jats:p>Only half of the patients with r\/mCC were treated 1L with platinum-combination therapy including antibody therapy according to national guidelines. Moreover, 22% at initial diagnosis and 38% of patients at PD were not treated with systemic therapy at all. This might reflect poor general performance status, patients\u2019 preference, and\/or lack of effective therapies especially in 2L treatment.<\/jats:p>","DOI":"10.1055\/a-2520-5736","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T22:33:53Z","timestamp":1747348433000},"page":"520-532","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study"],"prefix":"10.1055","volume":"85","author":[{"given":"Dominik","family":"Denschlag","sequence":"additional","affiliation":[{"name":"Hochtaunuskliniken Bad Homburg, Bad Homburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastian","family":"Czogalla","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Frauenheilkunde und Geburtshilfe, LMU Klinikum, LMU M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Heitz","sequence":"additional","affiliation":[{"name":"Evangelische Kliniken Essen-Mitte, Essen, Germany"},{"name":"Charit\u00e9 Campus Virchow-Klinikum, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Department for Gynecology with the Center for Oncologic Surgery, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7151-5875","authenticated-orcid":false,"given":"Markus","family":"Kerkmann","sequence":"additional","affiliation":[{"name":"MMF Research GmbH, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura-Christin","family":"Fangmann","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip H.","family":"Klecker","sequence":"additional","affiliation":[{"name":"Johannes-Gutenberg Universit\u00e4t Mainz, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-2064","authenticated-orcid":false,"given":"Frederik A.","family":"Stuebs","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linn","family":"W\u00f6lber","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Radosa","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinken des Saarlandes, Homburg\/Saar, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia C.","family":"Lodde","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gyn\u00e4kologie und gyn\u00e4kologische Onkologie, Universit\u00e4tsklinikum Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Seitz","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Frauenheilkunde und Geburtshilfe der Universit\u00e4t Regensburg, Regensburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"George","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsfrauenklinik und Poliklinik am Klinikum S\u00fcdstadt, Rostock, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Mach","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Fink","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Ulm, Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davit","family":"Bokhua","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Jena, Jena, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"deGregorio","sequence":"additional","affiliation":[{"name":"Klinikum am Gesundbrunnen, Heilbronn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Lampe","sequence":"additional","affiliation":[{"name":"St\u00e4dtische Klinik Elisabeth Krankenhaus M\u00f6nchengladbach, M\u00f6nchengladbach, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Hemptenmacher","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein Campus L\u00fcbeck, L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Friebe","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Fleisch","sequence":"additional","affiliation":[{"name":"Landesfrauenklinik, Helios-Universit\u00e4tsklinikum Wuppertal, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Wimberger","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t Dresden und NCT Dresden, Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jaeger","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf\/Onkologisches Therapiezentrum Hamburg, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Schnelzer","sequence":"additional","affiliation":[{"name":"RoMed-Klinikum Rosenheim, Rosenheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana","family":"Mittelstadt","sequence":"additional","affiliation":[{"name":"Diakonie Klinikum Schw\u00e4bisch Hall, Schw\u00e4bisch Hall, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Ratiu","sequence":"additional","affiliation":[{"name":"Universit\u00e4ts-Frauenklinik K\u00f6ln, K\u00f6ln, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Eichbaum","sequence":"additional","affiliation":[{"name":"Helios Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Haus","sequence":"additional","affiliation":[{"name":"GPR Klinikum R\u00fcsselsheim, R\u00fcsselsheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kalder","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Marburg, Marburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beyhan","family":"Ataseven","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinik f\u00fcr Frauenheilkunde und Geburtshilfe, Universit\u00e4t Bielefeld, Medizinische Fakult\u00e4t und Universit\u00e4tsklinikum OWL, Klinikum Lippe, Detmold, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willibald","family":"Schr\u00f6der","sequence":"additional","affiliation":[{"name":"Gynaekologicum Bremen, Bremen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Bronger","sequence":"additional","affiliation":[{"name":"Klinikum rechts der Isar Technische Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kosse","sequence":"additional","affiliation":[{"name":"Sana Klinikum Offenbach, Offenbach, Germany"},{"name":"Klinikum Hanau, Hanau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe Andreas","family":"Ulrich","sequence":"additional","affiliation":[{"name":"Martin-Luther-Krankenhaus Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Elser","sequence":"additional","affiliation":[{"name":"AGO Studiengruppe, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[{"name":"Evangelische Kliniken Essen-Mitte, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref4","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"HJ Long 3rd","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505","volume":"33","author":"R Kitagawa","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"BJ Monk","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"KS Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"KS Tewari","year":"2017","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"N Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"37","author":"HC Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with Cemiplimab in Recurrent Cervical Cancer","volume":"386","author":"KS Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"RL Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer","volume":"391","author":"I Vergote","year":"2024","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.18553\/jmcp.2023.29.5.490","article-title":"Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer","volume":"29","author":"CA Leath 3rd","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000527959","article-title":"Immune System Activation in Patients with Metastatic Renal Cell Carcinoma Induced by the Systemic Abscopal Effects of Radiation Therapy","volume":"46","author":"MA D\u2019Andrea","year":"2023","journal-title":"Oncol Res Treat"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2217\/fon-2020-0994","article-title":"The abscopal effect of radiation therapy","volume":"17","author":"DJ Craig","year":"2021","journal-title":"Future Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ygyno.2021.03.002","article-title":"Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis","volume":"161","author":"Z Alholm","year":"2021","journal-title":"Gynecol Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"111578","DOI":"10.1016\/j.intimp.2024.111578","article-title":"Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study","volume":"129","author":"C Peng","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1038\/s41416-023-02233-x","article-title":"Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse","volume":"128","author":"S Mittelstadt","year":"2023","journal-title":"Br J Cancer"}],"container-title":["Geburtshilfe und Frauenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2520-5736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T22:34:15Z","timestamp":1747348455000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2520-5736"}},"subtitle":["A Quality Assurance Initiative of the AGO-Study Group and AGO-OK Uterus"],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":16,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2520-5736","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0016-5751","1438-8804"],"issn-type":[{"value":"0016-5751","type":"print"},{"value":"1438-8804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}